Related coverage linked through entity extraction aliases.
Feb 16, 2026
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
Feb 16, 2026
Roche announced that Gazyva/Gazyvaro met its primary endpoint in the Phase III MAJESTY study for primary membranous nephropathy, showing statistically significant complete remission rates versus tacrolimus. The drug could become the first approved therapy for this rare autoimmune kidney disease.
Feb 15, 2026
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
Feb 14, 2026
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
Feb 14, 2026
Disc Medicine received a complete response letter from the FDA for bitopertin as a treatment for erythropoietic protoporphyria. The FDA acknowledged the drug lowers PPIX levels but requires evidence from the ongoing Phase 3 APOLLO study before approval.
Feb 14, 2026
The FDA issued a Complete Response Letter for bitopertin in erythropoietic protoporphyria, acknowledging the drug lowers PPIX levels but requiring Phase 3 APOLLO trial results to demonstrate clinical benefit before approval.
Feb 14, 2026
The FDA rejected Disc Medicine's bitopertin for erythropoietic protoporphyria, citing uncertainties about clinical benefit despite the drug receiving a priority review voucher. The company will pursue traditional approval with Phase 3 data expected in late 2026.
Feb 13, 2026
Novartis US shares traded at all-time highs in early February 2026 despite expected generic competition, driven by sales above expectations and positive Phase 3 kidney drug data. The company's market capitalization reached $265.2 billion.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
Feb 14, 2026
Immunic announced an oversubscribed private placement of up to $400 million to complete phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive MS, and transition to a commercial organization.
Feb 13, 2026
Immunic announced an oversubscribed private placement of up to $400 million to complete Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive MS, and transition into a commercial organization.
